Navigation Links
MacroGenics Appoints New Chief Commercial Officer and Chief Financial Officer

ROCKVILLE, Md., May 6 /PRNewswire/ -- MacroGenics Inc, a private biotechnology company focused on the development of products to treat autoimmune disorders, cancers, and infectious diseases, today announced the appointments of Dr. Jean-Christophe Tellier as Executive Vice President and Chief Commercial Officer and Mr. James Karrels as Vice President and Chief Financial Officer. "We are very fortunate to attract two exceptionally talented professionals to the executive management team at MacroGenics," said Dr. Scott Koenig, President and CEO. "Both Jean-Christophe and Jim exhibit personal qualities and experiences that are among the best in the biotechnology and pharmaceutical industry, and they will complement the skills of our already extraordinary management group, as we position our company for growth and advance our pipeline towards commercialization."

Dr. Tellier joins MacroGenics after a distinguished 20 year career in commercial development at Novartis. Since February 2007, he served as Chairman and CEO of Novartis Pharma France and Novartis Group France. The Group comprises 2,800 employees with sales at Novartis Pharma France of about 1 billion, including marketed brand name products in cardiovascular, oncology, neurosciences, respiratory, dermatology, transplant/immunology, infectious diseases, and ophthalmology. Prior to this, Dr. Tellier was Head of the Global Business Franchise for Arthritis, Bone, and Muscle Disease headquartered in Basel. From January 2003 through September 2006, Dr. Tellier served as CEO of Novartis Pharma Belgium and Country President where he was responsible for all business units and support services and coordination of all product sectors including OTC, generics, and Ciba Vision. During this tenure, he became President of the Board of the Belgian Pharma Trade association (, the first non-Belgium citizen to be elected to this position. Dr. Tellier received his MD from the University of Reims Champagne- Ardenne and a post-graduate degree in rheumatology from the University of Paris V. In addition, he completed executive business programs at Harvard and INSEAD.

"Jean-Christophe's depth and breadth of international business experiences in leadership positions at Novartis and in the pharmaceutical industry add a new dimension to our organization," stated Dr. Koenig. "As a trained rheumatologist and expert in drug development and marketing, Dr. Tellier brings an unusual combination of skills to MacroGenics that will enhance our ability to advance the lead product in autoimmunity to the marketplace."

Mr. James Karrels brings a wealth of financial and analytical experience to MacroGenics. He has been at Jazz Pharmaceuticals, Inc. since 2005, most recently serving as Executive Director of Finance. While at Jazz Pharmaceuticals, he was responsible for the company's financial planning and analysis and investor relations activities. He began his career as an analyst at Merrill Lynch & Co. in 1989 and advanced to the position of Director in the Healthcare Investment Banking Group. During his tenure there, he participated in more than 30 sole or lead-managed transactions, representing over $25 billion in aggregate transaction value. His activities included the marketing, structuring, and execution of IPOs, equity and convertible debt financings, mergers and acquisitions, spin-offs and other transactions. Mr. Karrels holds an M.B.A. from Stanford University and a B.B.A. from the University of Notre Dame.

"Jim joins us at an important juncture of the company's development. His combined experience in operations, finance and investment banking are especially important as we plan and execute on the growth of our business and advance to become a publicly-traded company," stated Dr. Koenig.

About MacroGenics, Inc.

Founded in 2000, MacroGenics is a private, venture-backed biotechnology company headquartered in Rockville, Maryland that focuses on the development, manufacture and commercialization of immunotherapeutics for autoimmune disorders, cancer and infectious diseases. In October 2007, Eli Lilly and Company (NYSE: LLY) and MacroGenics, Inc. announced a global strategic alliance to develop and commercialize teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules for use in the treatment of autoimmune diseases. Teplizumab is currently being studied in the PROTG trial, a global pivotal Phase II/III clinical trial for individuals with recent-onset type 1 diabetes. The company's proprietary DART (Dual Affinity Re-Targeting) and Fc engineering technologies offer ways to improve the function of antibodies and similar molecules. For more information about MacroGenics, please visit

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward- looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, and risks related to the Company's ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.

SOURCE MacroGenics Inc
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lilly and MacroGenics Announce Licensing and Collaboration Agreement
2. WorldHeart Appoints David Pellone Chief Financial Officer
3. Novo Nordisk Appoints New Leader of North American Business
4. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
5. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
6. Resonant Medical Appoints New Vice President of Global Sales
7. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
8. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
9. EPI-Q Opens East Coast Office and Appoints Vice President-Business Development
10. President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol
11. Governor Rendell Appoints Members of Chronic Care Commission as Part of Prescription for PA
Post Your Comments:
(Date:11/24/2015)... York, N.Y. (PRWEB) , ... November 24, 2015 , ... ... Giving Tuesday, the global movement driven by social media and the generosity of people ... Speaks, then encourage their social media networks to give – and share the personal ...
(Date:11/24/2015)... Tennessee (PRWEB) , ... November 24, 2015 , ... ... Pharmacy Quality Trend Report . Throughout the past year there have been multiple breakthroughs ... mature state. During this transition, PharmMD has enabled their customers and partners to stay ...
(Date:11/24/2015)... San Mateo, CA (PRWEB) , ... November 24, 2015 , ... “I am so thrilled, ... teacher Stephanie Lederman after learning she had won a $7,500 School Lounge Makeover® from ... Chandler, Arizona, where most of the staff has a much longer tenure. , “This is ...
(Date:11/24/2015)... ... November 24, 2015 , ... Add a fresh touch ... an easy and affordable way to bring long-lasting style and cheer to any space. ... oxygen, clean the air and keep on giving all year long. , “Holiday plants ...
(Date:11/24/2015)... ... ... Tudore Tranquility is a new restaurant in Tokyo, Japan that recently opened their ... is full of flavorful and creative dishes that exceed expectations. It is an elegant ... intimate event. The décor looks stunning with gold and beige tones. , Tudore ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... F1000Workspace - a research collaboration, reference management and ... six months ago. --> F1000Workspace - a ... since it was launched just six months ago. --> ... F1000Workspace - a research collaboration, reference management and authoring ... months ago. --> --> ...
(Date:11/24/2015)... , Nov. 24, 2015  Family Rentals, ... recently announced the launch of their newly designed, ... --> --> ... --> --> Now, renting ... travel and vacation, just got a whole lot ...
(Date:11/24/2015)... Pa. , Nov. 24, 2015  NuShield, Inc., an industry leader in LCD screen protection ... and stationary computer technology as part of their patient monitoring or electronic documentation system. ... ... ... A ...
Breaking Medicine Technology: